Founder and CEO, THOR Photomedicine Ltd
Photobiomodulation (PBM) is a emerging treatment for Oral Mucositis, it is recommended by NICE and has 47 randomised controlled clinical trials to support its use. James Carroll has been a pioneer in the field of Photobiomodulation since 1987, is Founder and CEO of THOR Photomedicine, Co-authored 24 PBM papers and contributed chapters to 5 PBM books. He is a recognised authority on PBM mechanism of action and dose-rate effects. APPOINTMENTS: Co-chair of the Biomedical Optics Society conference on Photobiomodulation mechanisms and a Fellow of The Royal Society of Medicine. NOTABLE SPEAKING EVENTS: US Congressional briefing on PBM as a solution for the opioid crisis, White House briefing on PBM as a solution for the opioid crisis and United Nations Global Health Impact Forum on PBM for Dry AMD. AWARDS: 2020 World Association for Photobiomodulation Therapy, Presidential Commendation for service and leadership in the field of Photobiomodulation. 2021 T.H. Maiman Award for excellence in medical laser research.